Related Experiment Video
Updated: Sep 21, 2025

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
Published on: June 4, 2021
Designing of disruptor molecules to restrain the protein-protein interaction network of VANG1/SCRIB/NOS1AP using
Suchandra Roy Acharyya1, Plaboni Sen1, Thirukumaran Kandasamy1
1Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 39, India.
Abstract:
Governing protein-protein interaction networks are the cynosure of cell signaling and oncogenic networks. Multifarious processes when aligned with one another can result in a dysregulated output which can result in cancer progression. In the current research, one such network of proteins comprising VANG1/SCRIB/NOS1AP, which is responsible for cell migration, is targeted. The proteins are modeled using in-silico approaches, and the interaction is visualized utilizing protein-protein docking. Designing drugs for the convoluted protein network can serve as a challenging task that can be overcome by fragment-based drug designing, a recent game-changer in the computational drug discovery strategy for protein interaction networks. The model is exposed to the extraction of hotspots, also known as the restrained regions for small molecular hits. The hotspot regions are subjected to a library of generated fragments, which are then recombined and rejoined to develop small molecular disruptors of the macromolecular assemblage. Rapid screening methods using pharmacokinetic tools and 2D interaction studies resulted in four molecules that could serve the purpose of a disruptor. The final validation is executed by long-range simulations of 100 ns and exploring the stability of the complex using several parameters leading to the emergence of two novel molecules VNS003 and VNS005 that could be used as the disruptors of the protein assembly VANG1/SCRIB/NOS1AP. Also, the molecules were explored as single protein targets approbated via molecular docking and 100 ns molecular dynamics simulation. This concluded VNS003 as the most suitable inhibitor module capable of acting as a disruptor of a macromolecular assembly as well as acting on individual protein chains, thus leading to the primary hindrance in the formation of the protein interaction complex.
Insights
Researchers identified novel small molecules, VNS003 and VNS005, to disrupt the VANG1/SCRIB/NOS1AP protein complex, a key player in cell migration and cancer progression. VNS003 shows particular promise as an inhibitor for both the complex and individual proteins.
Area of Science:
- Computational Biology
- Drug Discovery
- Cancer Research
Background:
- Protein-protein interaction networks are crucial for cell signaling and oncogenic pathways.
- Dysregulated protein interactions can drive cancer progression, making them key therapeutic targets.
- The VANG1/SCRIB/NOS1AP protein complex regulates cell migration and is implicated in cancer.
Purpose of the Study:
- To computationally model and analyze the VANG1/SCRIB/NOS1AP protein interaction network.
- To identify novel small molecules capable of disrupting this protein complex using fragment-based drug design.
- To validate the efficacy and stability of potential drug candidates through molecular dynamics simulations.
Main Methods:
- In-silico modeling and protein-protein docking were used to visualize the VANG1/SCRIB/NOS1AP complex.
- Fragment-based drug design identified hotspots within the protein complex for small molecule targeting.
- Pharmacokinetic screening, 2D interaction studies, and 100 ns molecular dynamics simulations validated drug candidates.
Main Results:
- Four potential small molecular disruptors were identified through rapid screening.
- Two novel molecules, VNS003 and VNS005, demonstrated stability and disruptive potential against the VANG1/SCRIB/NOS1AP complex.
- VNS003 was further validated as a potent inhibitor for both the protein assembly and individual protein targets.
Conclusions:
- Fragment-based drug design is an effective strategy for targeting complex protein-protein interactions.
- VNS003 and VNS005 represent promising novel therapeutic agents for inhibiting the VANG1/SCRIB/NOS1AP complex.
- VNS003 is a highly suitable candidate for further development as an anti-cancer therapeutic by disrupting critical protein interactions.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
06:26Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
Related Concept Videos
Protein-protein Interfaces
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...